Home » Stocks » CAPR

Capricor Therapeutics, Inc. (CAPR)

Stock Price: $4.45 USD 0.03 (0.68%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $4.76 +0.31 (6.97%) Jun 11, 7:14 PM
Market Cap 101.81M
Revenue (ttm) 165,373
Net Income (ttm) -16.72M
Shares Out 22.23M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $4.45
Previous Close $4.42
Change ($) 0.03
Change (%) 0.68%
Day's Open 4.39
Day's Range 4.33 - 4.47
Day's Volume 98,404
52-Week Range 3.13 - 12.32

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...

2 days ago - GlobeNewsWire

-Capricor's Findings Support Expansion Across Multiple Therapeutic Targets-

3 weeks ago - GlobeNewsWire

---Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy-

4 weeks ago - GlobeNewsWire

Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET

1 month ago - GlobeNewsWire

Capricor Therapeutics (NASDAQ: CAPR) has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of th...

1 month ago - Benzinga

Exosomes Platform Technology -Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine--Pipeline Expansion Underway Using Engineered Exosomes-

3 months ago - GlobeNewsWire

-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles-

3 months ago - GlobeNewsWire

-Technology Licensed from Johns Hopkins University-

4 months ago - GlobeNewsWire

-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-

4 months ago - GlobeNewsWire

—Capricor to leverage Lonza's expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply—

5 months ago - GlobeNewsWire

Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19 Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, t...

5 months ago - GlobeNewsWire

Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- - Novel Vaccine Induce d Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins - -Deve...

7 months ago - GlobeNewsWire

Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins

7 months ago - GlobeNewsWire

Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET

7 months ago - GlobeNewsWire

--Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnolog...

8 months ago - GlobeNewsWire

LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosom...

9 months ago - GlobeNewsWire

Capricor Therapeutics (NASDAQ: CAPR) shares are trading higher on Tuesday after the company announced the U.S.

9 months ago - Benzinga

– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 –

9 months ago - GlobeNewsWire

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Exosome Platform for COVID-19 -Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies- -Preclinical Data Shows Positive Antibody Response-

10 months ago - GlobeNewsWire

Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET

10 months ago - GlobeNewsWire

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

Capricor Therapeutics Inc. (CAPR) CEO Linda Marban on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Duchenne Muscular Dystrophy Program -Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Limb (PUL) 2....

1 year ago - GlobeNewsWire

Capricor Therapeutics Inc.’s (NASDAQ: CAPR) shares soared after data that pointed to a 100 percent survival rate in critical COVID-19 patients treated with new CAP-1002 cardiac cell therapy was released.

1 year ago - Benzinga

U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients

1 year ago - GlobeNewsWire

­LOS ANGELES, April 03, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the ...

1 year ago - GlobeNewsWire

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

Other stocks mentioned: MASI, MRNA, QGEN
1 year ago - Zacks Investment Research

Capricor Therapeutics' (CAPR) CEO Linda Marban on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Company Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program Company Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program

1 year ago - GlobeNewsWire

Is (CAPR) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for February 3rd

Other stocks mentioned: CLS, SNE, TROW
1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for January 28th

Other stocks mentioned: PERI, SNE, STM
1 year ago - Zacks Investment Research

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics f...

1 year ago - GlobeNewsWire

LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics f...

1 year ago - GlobeNewsWire

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Call Scheduled for Thursday, October 24th at 10:30am Eastern Time

1 year ago - GlobeNewsWire

--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies-- --Company to Host Conference Call Today at 5:30 AM PT / 8:30 AM ET--

1 year ago - GlobeNewsWire

Capricor Therapeutics shares CAPR, -0.32% rose 3.6% in premarket trade Tuesday, after the clinical-stage biotech said the U.s.

1 year ago - Market Watch

Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies Company Exploring Potential for Accelerated Approval under RMAT Designation, ...

1 year ago - GlobeNewsWire

Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation

1 year ago - GlobeNewsWire

LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for t...

1 year ago - GlobeNewsWire

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Capricor (CAPR) delivered earnings and revenue surprises of 26.25% and 86.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Capricor announced positive interim results from its phase 2 HOPE-2 study using CAP-1002 to treat patients with Duchenne muscular dystrophy.

1 year ago - Seeking Alpha

About CAPR

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials in... [Read more...]

Industry
Biotechnology
Founded
2005
CEO
Linda Marban
Employees
26
Stock Exchange
NASDAQ
Ticker Symbol
CAPR
Full Company Profile

Financial Performance

In 2020, CAPR's revenue was $310,250, a decrease of -69.13% compared to the previous year's $1.01 million. Losses were -$13.66 million, 78.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CAPR stock is "Buy" and the 12-month stock price forecast is 10.50.

Price Target
$10.50
Analyst Consensus: Buy